Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer

Aim: The aim of this multicenter study was to assess patient characteristics and short-term survival outcomes of first-line (1L) enfortumab vedotin plus pembrolizumab (EVP) as compared with conventional chemotherapy in locally advanced or metastatic urothelial carcinoma (la/mUC). Methods: The databa...

詳細記述

書誌詳細

主要な著者:	Makito Miyake, Nobutaka Nishimura, Yuki Oda, Takuto Shimizu, Takeshi Inoue, Satoshi Anai, Keichi Sakamoto, Yoshiaki Matsumura, Yuta Toyoshima, Daiki Ichii, Kota Iida, Takashi Iwamoto, Norimi Takamatsu, Atsushi Tomioka, Hiroaki Yamamoto, Fumisato Maesaka, Kiyohide Fujimoto, on behalf of the Nara Urological Research Treatment Group
フォーマット:	Artigo
言語:	Inglês
出版事項:	Open Exploration Publishing Inc. 2026-07-01
シリーズ:	Exploration of Targeted Anti-tumor Therapy
主題:	urothelial carcinoma chemotherapy response outcome enfortumab vedotin pembrolizumab adverse event
オンライン･アクセス:	https://www.explorationpub.com/uploads/Article/A1002379/1002379.pdf
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!